Navigation Links
Varian Medical Systems Showcases Advanced Radiotherapy and Brachytherapy Products at ACRO 2010, February 25-27, Florida, Booth No. 34-35
Date:2/22/2010

PALO ALTO, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) will be displaying its extensive range of radiotherapy and brachytherapy technology advancements at the annual American College of Radiation Oncology (ACRO) conference in Lake Buena Vista, Florida, later this week. Varian can be found on Booths 34 and 35.

In advance of the show, Varian is hosting an educational symposium on February 24th focusing on the practical implementation of high dose rate brachytherapy for prostate and gynecological cancer. Dr. James McGee, MD, from OSF Saint Francis Medical Center in Peoria, IL and Dr. Catheryn Yashar, MD, of the University of California, San Diego Medical Center in LaJolla, CA., will detail a number of clinical experiences and focus on treatment planning techniques and treatment workflow.

"We are delighted that two such eminent clinicians will be on hand to share their experiences of offering high dose rate brachytherapy treatments to cancer patients using Varian equipment and software," says Hosea Mitchell, head of Varian's brachytherapy business. "It is important for Varian, as the world leader in radiation oncology equipment and software, to be present at the American College of Radiation Oncology meeting and we are pleased to extend our partnership with this key organization."

Varian will also be highlighting its leading external beam technologies in a sponsored symposium at the show on February 25th. Techniques for intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery and RapidArc® volumetric modulated arc therapy will be described in a symposium with experts including Dr. McGee and Dr. John Fiveash, MD, of the University of Alabama, Birmingham, AL.  

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,000 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.

SOURCE Varian Medical Systems, Inc.

Back to top

RELATED LINKS
http://www.varian.com

'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
(Date:2/23/2017)... This report analyzes analyzes the worldwide markets for Wound Debridement Products ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena ... 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... online directory that recognizes local physicians and dentists who have earned high ratings and ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... ... 2017 , ... Healthcare Research & Analytics® (HRA®) in cooperation ... cancer, has produced a seminal study that asked cancer survivors and their caregivers ... a webinar, Defining Compassionate Care Through the Voices of Patients and Advocates that ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
Breaking Medicine News(10 mins):